Business
Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology
Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase 1/2, global, multicenter study of zipalertinib (development code: CLN-081/TAS6417) in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who have received prior therapy. Results from the REZILIENT1 tria
About this update from Cullinan Therapeutics, Inc.
[{"type":"text","content":"PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase 1/2, global, multicenter study of zipalertinib (development code: CLN-081/TAS6417) in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who have received prior therapy. Results from the REZILIENT1 trial will be presented in a simultaneous oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #8503).","length":717,"tagName":"p"},{"type":"image","alt":"Cullinan Therapeutics","displaySize":"","headline":null,"caption":"Cullinan Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":209,"url":"https://media.zenfs.com/en/prnewswire.com/85a0de6e6a5f84b49acb997712f48484"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_9Jsf9sbkmZ02584MujHHA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/85a0de6e6a5f84b49acb997712f48484","width":400,"height":209}},"href":"https://mma.prnewswire.com/media/2700345/Culligan.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The full publication, titled Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab, can be found here.","length":245,"tagName":"p"},{"type":"text","content":"Highlights of the REZILIENT1 Phase 1/2 trial in the authors' conclusions include:","length":85,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Zipalertinib demonstrated clinically meaningful efficacy in the primary efficacy population (n=176), including 51 patients who had received prior amivantamab.","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"The confirmed objective response rate (ORR) was 35.2% overall, and median duration of response (mDOR) and progression-free survival were 8.8 months and 9.4 months, respectively.","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"In patients treated after prior platinum-...